

## Vilanterol

## Chemical Properties

CAS No. : 503068-34-6


Formula: C<sub>24</sub>H<sub>33</sub>Cl<sub>2</sub>NO<sub>5</sub>

Molecular Weight: 486.43

Appearance: no data available

keep away from moisture

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year



## Biological Description

Description	Vilanterol is a selective long-acting beta2-adrenergic agonist (LABA) used in the treatment of COPD and asthma.
Targets(IC50)	Adrenergic Receptor
In vitro	The selectivity of Vilanterol for $\beta_2$ -AR over other $\beta$ -AR receptor subtypes ( $\beta_2$ and $\beta_3$ ) is demonstrated through its ability to elicit concentration-dependent increases in cAMP in CHO cells expressing human $\beta_1$ -, $\beta_2$ -, and $\beta_3$ -AR. Vilanterol shows high selectivity for $\beta_2$ -AR with at least a 1000-fold preference over $\beta_2$ - and $\beta_3$ -AR subtypes. This analysis yields a low-affinity pKD for [3H]Vilanterol of $9.44 \pm 0.07$ (n=4) in the presence of Gpp(NH)p and a high-affinity pKD of $10.82 \pm 0.12$ (n=4) and a low-affinity pKD of $9.47 \pm 0.17$ (n=4) in the absence of Gpp(NH)p. Additionally, a low-affinity pKD of $9.52 \pm 0.24$ (n=4) is observed for [3H]Vilanterol in the absence of Gpp(NH)p at 37°C. Vilanterol trifenate is a novel inhaled long-acting $\beta_2$ -agonist with 24-hour activity in vitro, developed in combination with the inhaled corticosteroid fluticasone furoate for the treatment of both COPD and asthma. Vilanterol is a novel long-acting $\beta_2$ -agonist (LABA) with 24-hour activity, intended for once-daily clinical treatment of COPD and asthma in combination with the 24-hour active corticosteroid fluticasone furoate.
Kinase Assay	Saturation, association, and dissociation binding studies are performed for [3H] Vilanterol to determine receptor binding kinetics at the $\beta_2$ -AR (equilibrium dissociation constant (KD), total number of receptors (Bmax), association rate (kon), and dissociation rate (koff) are calculated). For saturation binding, membranes (in a volume of 1.4 mL to avoid ligand depletion) are incubated with increasing concentrations of [3H]Vilanterol (~0.01-1.3 nM) for 5 h before filtration. For association binding, membranes are incubated with different concentrations of [3H]Vilanterol (~0.1-1.9 nM) for varying incubation times up to 1 h before filtration. For dissociation binding, membranes are preincubated for 1 h with a fixed concentration of [3H]Vilanterol (~1.1 nM) before dissociation is initiated by a 1:20 dilution in binding buffer (containing 10 $\mu$ M cold Vilanterol) and then incubated for varying times up to 8 h before filtration. Saturation binding is also completed for [3H]CGP12177 (increasing concentrations of ~0.01-2.8 nM) in the same format as described above for [3H]Vilanterol. To determine the affinity of $\beta_2$ -AR agonists and antagonists, competition binding displacement studies are completed in which membranes are incubated with a fixed concentration of [3H]

Vilanterol (~0.2 nM) and increasing concentrations of unlabeled agonist/antagonist for 5 h before filtration. All competition binding displacement studies are completed in the presence of 100  $\mu$ M Gpp(NH)p to ensure that binding curves are monophasic[1].

### Solubility Information

Solubility	DMSO: 50 mg/mL (102.79 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0558 mL	10.279 mL	20.5579 mL
5 mM	0.4112 mL	2.0558 mL	4.1116 mL
10 mM	0.2056 mL	1.0279 mL	2.0558 mL
50 mM	0.0411 mL	0.2056 mL	0.4112 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Kempsford R, et al. Vilanterol trifenate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. *Pulm Pharmacol Ther.* 2013 Apr;26(2):256-  
Harrell A W , Siederer S K , Bal J , et al. Metabolism and Disposition of Vilanterol, a Long-Acting 2-Adrenoceptor Agonist for Inhalation Use in Humans[J]. *Drug Metabolism and Disposition*, 2013, 41(1):89-100.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481